中金:维持远大医药“跑赢行业”评级 升目标价至9.6港元

新浪网
14 May

中金发布研报称,维持远大医药2025年/2026年EPS预测0.6/0.63港币不变。当前股价对应2025年/2026年13.9倍/13.2倍市盈率。该行维持“跑赢行业”评级,考虑到公司RDC管线接近收获,上调目标价20.0%至9.6港币,对应2025年/2026年16.0倍/15.2倍市盈率,较当前股价有15.4%的上行空间。中金主要观点如下:公司近况5月12日,公司公告创新核素偶联药物(RDC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10